Evidence map›Paper›PMID 31797086›Full record

Observational studyJournal of neurology2020

Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life.

Raphael Scherbaum, Elke Hartelt, Manuel Kinkel, Ralf Gold, Siegfried Muhlack, Lars Tönges

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Multidisciplinary care in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Raphael ScherbaumDepartment of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany.
Elke HarteltDepartment of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany.
Manuel KinkelPsychiatrische Gutachtenpraxis, Bochum, Germany.
Ralf GoldDepartment of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany.
Siegfried MuhlackDepartment of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany.
Lars TöngesDepartment of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany. lars.toenges@rub.de.ORCID http://orcid.org/0000-0001-6621-144X
St. Josef-Hospital · DEUniversity Hospitals of the Ruhr-University of Bochum · DE

Funding

Deutsche Parkinson Vereinigung Bundesverband 33.17-92907
6 · The paper itself

Abstract

Parkinson's disease (PD) is the world's fastest growing neurological disorder disabling patients through a broad range of motor and non-motor symptoms. For the clinical management, a multidisciplinary approach has increasingly been shown to be beneficial. In Germany, inpatient Parkinson's Disease Multimodal Complex Treatment (PD-MCT) is a well-established and frequent approach, although data on its effectiveness are rare. We conducted a prospective real-world observational study in 47 subjects [age (M ± SD): 68.5 ± 9.0 years, disease duration: 8.5 ± 5.3 years, modified Hoehn and Yahr stage (median, IQR): 3, 2.5-3] aiming at evaluating the effectiveness of 14-day PD-MCT in terms of quality of life (Parkinson's Disease Questionnaire, EuroQol), motor [Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III], Timed Up and Go Test, Purdue Pegboard Test) and non-motor symptoms (revised Beck Depression Inventory). Six weeks after hospital discharge, a follow-up examination was performed. PD patients with a predominantly moderate disability level benefited from PD-MCT in terms of health-related quality of life, motor symptoms and non-motor symptoms (depression). Significant improvements were found for social support, emotional well-being and bodily discomfort domains of health-related quality of life. Sustainable improvement occurred for motor symptoms and the subjective evaluation of health state. We found a higher probability of motor response especially for patients with moderate motor impairment (MDS-UPDRS III ≥ 33). In conclusion, Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life. A more detailed selection of patients who will benefit best from this intervention should be examined in future studies.

Indexed as

Outcome Assessment, Health CareQuality of LifeAgedCombined Modality TherapyDepressionDyskinesiasExercise TherapyFemaleFollow-Up StudiesHumansHyperthermia, InducedLanguage TherapyMaleMassageMiddle AgedNeurological RehabilitationInpatientMultidisciplinary careParkinson’s diseaseQuality of life

Identifiers

PMID31797086
OpenAlexW2992035714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.